GW Pharma (GWPH) Gains ~13% on Positive Epidiolex Data in LGS

September 26, 2016 7:55 AM EDT

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

GW Pharma (NASDAQ: GWPH) shares are trading up 12.9% after the company announced positive results of the second randomized, double-blind, placebo-controlled Phase 3 clinical trial of its investigational medicine Epidiolex (cannabidiol or CBD) for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), a rare and severe form of childhood-onset epilepsy.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

FDA, Hot FDA News, Momentum Movers, Trader Talk

Add Your Comment